Liquidia (LQDA) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Liquidia Corporation  (NASDAQ: LQDA)


Liquidia's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Liquidia's ROA in the second quarter of 2026?
Liquidia Corporation achieved a return on average assets (ROA) of 36.48 % in its second quarter of 2026, this is above LQDA's average return on assets of -56.46%.
Liquidia Corporation assets over the 12 months ending in its second quarter of 2026 are valued at $380 million

ROA has improved compared to 7.11% in the first quarter of 2026, due to net income growth.

However, within the Healthcare sector 28 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 890, from total ROA ranking in the first quarter of 2026 at 4176.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 102.76 % 76.55 % 48.75 % 9.02 % 50.66 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 139 22 -69 -122 -149
Return On Assets (TTM) 36.48 % 7.11 % -25.5 % -50.12 % -62.85 %
LQDA's Total Ranking # 890 # 4176 # 4011 # 4202 # 4280
Total Assets (TTM) in million 522 402 328 268 257
Seq. Total Assets Change 29.98 % 22.44 % 22.22 % 4.24 % 13.18 %
Seq. Net Income Change 41.35 % 263.19 % - - -

LQDA's 5 Years Annual ROA >> Back to LQDA Management Effectiveness >> Compare LQDA ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 16
Sector # 29
Overall # 100

Return On Assets Statistics
High Average Low
36.3 %
-56.46 %
-149.39 %
(Jun 30 2026)   (Dec 31 2018)





Financial Statements
Liquidia's Assets $ 522 million LQDA's Balance sheet
Liquidia's Income $ 75 million Quarterly LQDA's Income Statement
LQDA's Income by Division See LQDA's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 48.75 % 95.6 % -7.3 % 47.23 % -4.32 %
Total Assets in million 328 220 113 122 83
Y / Y Net Income Change - - - - -
Net Income in million -69 -130 -79 -41 -35
Annual Return On Assets -21.02 % -59.15 % -69.65 % -33.73 % -41.87 %

LQDA's 5 Years Annual ROA >> Back to LQDA Management Effectiveness >> Compare LQDA ROA to its Competitors



More Return On Assets Ratios
LQDA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
LQDA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for LQDA's Competitors
Subscribers only: Roa for Liquidia's Suppliers
Subscribers only: Return On Assets for LQDA's Customers

You may also want to know
LQDA's Roi LQDA's Inventory Turnover Ratio LQDA's Growth Rates LQDA's Dividend Comparisons
LQDA's Profitability Ratios LQDA's Asset Turnover Ratio LQDA's Dividend Growth
LQDA's Roe LQDA's Valuation Ratios LQDA's Financial Strength Ratios LQDA's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA
Silexion Therapeutics Corp  99.09 %
Arbutus Biopharma Corp  96.04 %
Pulmatrix Inc   94.81 %
Quince Therapeutics Inc   88.46 %
Interpace Biosciences Inc   85.91 %
Oncotelic Therapeutics Inc   81.75 %
Rigel Pharmaceuticals Inc  72.27 %
Actinium Pharmaceuticals Inc  71.73 %
Sanuwave Health Inc   71.60 %
Exelixis Inc   70.51 %
Rallybio Corporation  64.51 %
Oramed Pharmaceuticals Inc  64.18 %
Fortress Biotech Inc   60.88 %
Atlantic Coastal Acquisition Corp Ii  54.09 %
Lensar Inc   47.48 %
Elite Pharmaceuticals Inc   46.11 %
Omeros Corporation  46.05 %
Q32 Bio Inc   45.18 %
Aurinia Pharmaceuticals Inc   44.95 %
Agenus Inc  44.86 %
Earth Science Tech Inc   44.02 %
Liquidia Corporation  36.30 %
Ironwood Pharmaceuticals inc   34.34 %
Idexx Laboratories Inc  33.61 %
Tg Therapeutics Inc   33.59 %
Meiragtx Holdings Plc  29.37 %
Indivior Pharmaceuticals Inc   28.21 %
Qhslab Inc   27.12 %
Adma Biologics Inc   26.58 %
Mettler toledo International Inc   24.86 %

Date modified: 2026-09-26T07:39:03+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.